Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
The study was designed to test the hypothesis whether a standardized, time-and score-oriented treatment following a strict evidence based algorithm is equally effective to a standard treatment regimen for moderate to severe atopic dermatitis.
Study Type: Mono-centre study, patients are blinded, physicians are randomized to either treat study- or controll group
Eligible are patients age 2 years or older with SCORAD >= 20 Duration: 12 Months, study visits every 4 weeks.
Primary endpoint is Difference between Baseline SCORAD and mean SCORAD under treatment.
Secundary endpoints are quality of life, safety and economic burden in both treatment groups.
Moderate to Severe Atopic Dermatitis
Drug: Ciclosporin A
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00148746
|Department of Dermatology, TU Dresden|
|Dresden, Germany, 01307|
|Study Director:||Jochen M Schmitt, MD, MPH||Dpt. of Dermatology, Medical Faculty, Technical University Dresden, Germany|